Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Predicting atrial fibrillation in primary care using machine learning.

Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O'Neill M, Clifton D, Gordon J.

PLoS One. 2019 Nov 1;14(11):e0224582. doi: 10.1371/journal.pone.0224582. eCollection 2019.

2.

Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database.

Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, Middeldorp S, Ageno W, Cohen AT, Hunt BJ, Konstantinides SV.

Lancet Respir Med. 2019 Oct 11. pii: S2213-2600(19)30354-6. doi: 10.1016/S2213-2600(19)30354-6. [Epub ahead of print]

PMID:
31615719
3.

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals.

Martin AC, Huang W, Goldhaber SZ, Hull RD, Hernandez AF, Gibson CM, Anderson FA, Cohen AT.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619880008. doi: 10.1177/1076029619880008.

PMID:
31588785
4.

Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.

Ageno W, Lopes RD, Yee MK, Hernandez A, Hull R, Goldhaber SZ, Gibson CM, Cohen AT.

J Thromb Thrombolysis. 2019 Sep 6. doi: 10.1007/s11239-019-01943-5. [Epub ahead of print]

PMID:
31493287
5.

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.

Ageno W, Lopes RD, Yee MK, Hernandez A, Hull RD, Goldhaber SZ, Gibson CM, Cohen AT.

J Thromb Haemost. 2019 Aug 8. doi: 10.1111/jth.14600. [Epub ahead of print]

PMID:
31392827
6.

Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.

Laskier V, Guy H, Fisher M, Neuman WR, Bucior I, Cohen AT, Ren S.

J Med Econ. 2019 Oct;22(10):1063-1072. doi: 10.1080/13696998.2019.1645679. Epub 2019 Aug 9.

PMID:
31314619
7.

Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial.

Yee MK, Gibson CM, Nafee T, Kerneis M, Daaboul Y, Korjian S, Chi G, AlKhalfan F, Hernandez AF, Hull RD, Cohen AT, Goldhaber SZ.

TH Open. 2019 Apr 17;3(2):e103-e108. doi: 10.1055/s-0039-1685496. eCollection 2019 Apr.

8.

Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.

Guy H, Laskier V, Fisher M, Bucior I, Deitelzweig S, Cohen AT.

Expert Rev Pharmacoecon Outcomes Res. 2019 Jun 19:1-9. doi: 10.1080/14737167.2019.1629905. [Epub ahead of print]

PMID:
31215264
9.

Rivaroxaban and the EINSTEIN clinical trial programme.

Cohen AT, Bauersachs R.

Blood Coagul Fibrinolysis. 2019 Apr;30(3):85-95. doi: 10.1097/MBC.0000000000000800. Review.

10.

Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study.

Field TS, Weijs B, Curcio A, Giustozzi M, Sudikas S, Katholing A, Wallenhorst C, Weitz JI, Cohen AT, Martinez C.

Thromb Haemost. 2019 Jun;119(6):981-991. doi: 10.1055/s-0039-1683429. Epub 2019 Mar 27.

PMID:
30919384
11.

Anticoagulant selection for patients with VTE-Evidence from a systematic literature review of network meta-analyses.

Cohen AT, Berger SE, Milenković D, Hill NR, Lister S.

Pharmacol Res. 2019 May;143:166-177. doi: 10.1016/j.phrs.2019.03.017. Epub 2019 Mar 21. Review.

12.

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Cate VT, Lensing AWA, Weitz JI, Beyer-Westendorf J, Wells PS, Mismetti P, Prandoni P, Cohen AT, Davidson BL, Prins MH.

Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7. No abstract available.

13.

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.

Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ.

Circulation. 2019 Feb 26;139(9):1234-1236. doi: 10.1161/CIRCULATIONAHA.118.038654. No abstract available.

PMID:
30802169
14.

Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.

Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ.

Intensive Care Med. 2019 Apr;45(4):477-487. doi: 10.1007/s00134-019-05565-6. Epub 2019 Feb 18.

PMID:
30778649
15.

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

Barco S, Granziera S, Coppens M, Douxfils J, Nijkeuter M, Riva N, Vanassche T, Zhang G, Lin M, Kamphuisen PW, Cohen AT, Beyer-Westendorf J.

Thromb Haemost. 2019 Apr;119(4):675-684. doi: 10.1055/s-0039-1678546. Epub 2019 Feb 7.

PMID:
30731492
16.

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators.

N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7.

17.

Magnitude of Venous Thromboembolism Risk in US Hospitals: Impact of Evolving National Guidelines for Prevention of Venous Thromboembolism.

Huang W, Cohen AT, Martin AC, Anderson FA.

Am J Med. 2019 May;132(5):588-595. doi: 10.1016/j.amjmed.2018.12.028. Epub 2019 Jan 16.

PMID:
30658087
18.

Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.

Cohen AT, Agnelli G, Buller HR, Gallus A, Raskob GE, Sanders P, Thompson J, Weitz JI.

Thromb Haemost. 2019 Mar;119(3):461-466. doi: 10.1055/s-0038-1676983. Epub 2019 Jan 16.

19.

Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.

Chuang LH, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Gitt AK, Monreal M, Willich SN, van Hout B.

Qual Life Res. 2019 May;28(5):1155-1177. doi: 10.1007/s11136-018-2081-3. Epub 2019 Jan 3.

PMID:
30607785
20.

Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.

Guy H, Laskier V, Fisher M, Neuman WR, Bucior I, Deitelzweig S, Cohen AT.

Pharmacoeconomics. 2019 May;37(5):701-714. doi: 10.1007/s40273-018-0757-8.

PMID:
30578462
21.

Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use.

Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT.

Semin Hematol. 2018 Oct;55(4):182-184. doi: 10.1053/j.seminhematol.2017.08.002. Epub 2017 Aug 12.

PMID:
30502844
22.

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.

Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ.

Thromb Haemost. 2018 Dec;118(12):2046-2052. doi: 10.1055/s-0038-1675606. Epub 2018 Nov 12.

PMID:
30419597
23.

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.

Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT.

Thromb Haemost. 2018 Nov;118(11):1951-1961. doi: 10.1055/s-0038-1673689. Epub 2018 Oct 24.

24.

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.

Chi G, Gibson CM, Liu Y, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ.

Am J Hematol. 2019 Jan;94(1):21-28. doi: 10.1002/ajh.25296. Epub 2018 Oct 17.

PMID:
30252149
25.

Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work.

Chuang LH, van Hout B, Cohen AT, Gumbs PD, Kroep S, Bauersachs R, Gitt A, Monreal M, Willich SN, Agnelli G.

Thromb Res. 2018 Oct;170:165-174. doi: 10.1016/j.thromres.2018.08.001. Epub 2018 Aug 4.

26.

COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study.

Cohen AT, Maraveyas A, Beyer-Westendorf J, Lee AYY, Mantovani LG, Bach M; COSIMO Investigators.

Thromb J. 2018 Sep 4;16:21. doi: 10.1186/s12959-018-0176-2. eCollection 2018.

27.

Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.

Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, Büller HR.

Thromb Haemost. 2017 Oct;117(10):1944-1951. doi: 10.1160/TH16-12-0946. Epub 2017 Nov 28.

PMID:
30151820
28.

Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.

Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI.

Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.

PMID:
30064683
29.

A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.

Cohen AT, Hill NR, Luo X, Masseria C, Abariga SA, Ashaye AO.

Int J Cardiol. 2018 Oct 15;269:174-181. doi: 10.1016/j.ijcard.2018.06.114. Epub 2018 Jun 30.

30.

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK.

Clay E, Jamotte A, Verhamme P, Cohen AT, Van Hout BA, Gumbs P.

J Mark Access Health Policy. 2018 Jul 17;6(1):1495974. doi: 10.1080/20016689.2018.1495974. eCollection 2018.

31.

Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.

Martinez C, Wallenhorst C, Teal S, Cohen AT, Peacock AJ.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018791358. doi: 10.1177/2045894018791358. Epub 2018 Jul 9.

32.

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients.

Cohen AT.

Eur Heart J Suppl. 2018 May;20(Suppl E):E1-E2. doi: 10.1093/eurheartj/suy014. Epub 2018 May 9. No abstract available.

33.

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators.

Thromb J. 2018 May 31;16:18. doi: 10.1186/s12959-018-0173-5. eCollection 2018.

34.

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators.

Thromb J. 2018 May 1;16:9. doi: 10.1186/s12959-018-0163-7. eCollection 2018. Erratum in: Thromb J. 2018 May 31;16:18.

35.

Significance of green granules in neutrophils and monocytes.

Gorup T, Cohen AT, Sybenga AB, Rappaport ES.

Proc (Bayl Univ Med Cent). 2017 Dec 29;31(1):94-96. doi: 10.1080/08998280.2017.1391045. eCollection 2018 Jan.

36.

Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.

Chi G, Gibson CM, Hernandez AF, Hull RD, Kazmi SHA, Younes A, Walia SS, Pitliya A, Singh A, Kahe F, Kalayci A, Nafee T, Kerneis M, AlKhalfan F, Cohen AT, Harrington RA, Goldhaber SZ.

Am J Med. 2018 Aug;131(8):972.e1-972.e7. doi: 10.1016/j.amjmed.2018.03.031. Epub 2018 Apr 13.

PMID:
29660351
37.

State of play and future direction with NOACs: An expert consensus.

Cohen AT, Lip GY, De Caterina R, Heidbuchel H, Zamorano JL, Agnelli G, Verheugt F, Camm AJ.

Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29656119
38.

Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.

Gibson CM, Nafee T, Yee MK, Chi G, Korjian S, Daaboul Y, AlKhalfan F, Kerneis M, Goldhaber SZ, Hull R, Hernandez AF, Cohen AT, Harrington RA.

Am Heart J. 2018 Apr;198:84-90. doi: 10.1016/j.ahj.2017.12.015. Epub 2017 Dec 27.

PMID:
29653652
39.

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, Renni M, Young AM.

Oncologist. 2018 Jul;23(7):822-839. doi: 10.1634/theoncologist.2017-0473. Epub 2018 Apr 12. Review.

40.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

41.

Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.

Gibson CM, Jennings LK, Chi G, Yee MK, Halaby R, Nafee T, AlKhalfan F, Kerneis M, Korjian S, Daaboul Y, Goldhaber SZ, Hull RD, Hernandez AF, Cohen AT, Harrington RA.

TH Open. 2018 Jan 8;2(1):e16-e24. doi: 10.1055/s-0037-1615288. eCollection 2018 Jan.

42.

Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent.

Brekelmans MPA, Büller HR, Mercuri MF, Ageno W, Chen CZ, Cohen AT, van Es N, Grosso MA, Medina AP, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI.

TH Open. 2018 Jan 8;2(1):e1-e7. doi: 10.1055/s-0037-1615251. eCollection 2018 Jan.

43.

Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.

Kraaijpoel N, van Es N, Bleker SM, Brekelmans MPA, Eerenberg ES, Middeldorp S, Cohen AT, Raskob GE, Büller HR.

Thromb Haemost. 2018 Jan;118(1):174-181. doi: 10.1160/TH17-04-0274. Epub 2018 Jan 5.

PMID:
29304537
44.

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.

Circulation. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187. No abstract available.

PMID:
29279341
45.

Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.

Vanassche T, Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Chen CZ, Cohen AT, Grosso MA, Medina AP, Mercuri MF, Winters SM, Zhang G, Weitz JI, Raskob GE, Büller HR.

Thromb Res. 2018 Feb;162:7-14. doi: 10.1016/j.thromres.2017.12.005. Epub 2017 Dec 13.

PMID:
29248859
46.

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.

Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.

Thromb Haemost. 2017 Dec;117(12):2406-2414. doi: 10.1160/TH17-05-0523. Epub 2017 Dec 6.

47.

Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.

Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, Gibson CM.

Thromb Haemost. 2017 Dec;117(12):2389-2395. doi: 10.1160/TH17-08-0538. Epub 2017 Dec 6.

PMID:
29212126
48.

Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.

J Thromb Thrombolysis. 2018 Jan;45(1):1-8. doi: 10.1007/s11239-017-1583-0.

PMID:
29188425
49.

Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism.

Barrios D, Morillo R, Guerassimova I, Barbero E, Escobar-Morreale H, Cohen AT, Becattini C, Tapson V, Yusen R, Jimenez D.

PLoS One. 2017 Nov 6;12(11):e0187648. doi: 10.1371/journal.pone.0187648. eCollection 2017.

50.

N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.

Chi G, Januzzi JL, Korjian S, Daaboul Y, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Cohen AT, Harrington RA, Gibson CM.

J Thromb Thrombolysis. 2017 Nov;44(4):457-465. doi: 10.1007/s11239-017-1552-7.

PMID:
28905172

Supplemental Content

Loading ...
Support Center